An 8-week randomized, open label, multi-center study to study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest